The role of adiponectin in human vascular physiology

Vaiopoulos, Aristeidis G.; Marinou, Kyriakoula; Christodoulides, Constantinos; Koutsilieris, Michael

doi:10.1016/j.ijcard.2011.07.047

Cited by 87 publications

(60 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Women have circulating adiponectin levels approximately 40% higher than men. 5,11 Interestingly, visceral fat compartments are largely responsible for the secretion of adiponectin, when compared to subcutaneous deposits. This is of particular interest because of the close association between visceral obesity and metabolic/cardiovascular disease; however, in vitro and in vivo studies performed in humans have shown that adipocytes with exhausted lipid storage, filled with fatty acids, and located in the intra-abdominal region can inhibit transcription of the adiponectin gene by secreting inflammatory and angiogenic factors, reducing its plasma levels.…”

Section: Biosynthesis Of Adiponectin and Receptorsmentioning

confidence: 99%

“…Adiponectin can also be detected in breast milk and cerebrospinal fluid, although in low concentrations. 11 The role of adiponectin is mediated by receptors known as adiponectin receptors 1 and 2 (Adipor1 and Aipor2). These receptors have seven transmembrane portions, but are functionally different from the G proteincoupled receptors, particularly because they have opposite polarity (i.e., the N-terminal faces the intracellular compartment).…”

Section: Biosynthesis Of Adiponectin and Receptorsmentioning

confidence: 99%

“…26 Furthermore, in humans, plasma adiponectin levels are positively associated with arterial vasodilation in response to nitroglycerin (an endotheliumindependent vasodilation measure), which does not depend on insulin sensitivity. 11 Adiponectin inhibits the production of proinflammatory cytokines and chemokines in endothelial cells, diminishing its ability to become activated in response to several inflammatory stimuli. Adiponectin also down-regulates receptor expression.…”

Section: Obesity and Adiponectinmentioning

confidence: 99%

See 2 more Smart Citations

Relationship between adiponectin, obesity and insulin resistance

Balsan¹,

Vieira²,

Oliveira³

et al. 2015

Rev. Assoc. Med. Bras.

144

100

View full text Add to dashboard Cite

Conflict of interest: noneObjectives: the conditions of obesity and overweight pose a major risk for a number of comorbidities, including clinical syndromes resulting from atherosclerotic disease. Recent studies strongly indicate that adipose tissue is an active endocrine organ that secretes bioactive factors such as adipokines. Adiponectin appears to have a regulatory role in the mechanism of insulin resistance and in the development of atherosclerosis. This systematic review aims to evaluate the anti-atherogenic effects of adiponectin and its properties to improve and mimic metabolic and vascular actions of insulin and its influence on endothelial function. Methods: a qualitative, exploratory and literature review was performed in the PubMed, Portal Capes and Scielo databases using as key-words "adiponectin", "obesity", "insulin resistance", "anti-inflammatory", "therapeutic strategies" and "future prospects". Results: evidence suggests that adiponectin has anti-atherogenic properties with anti-inflammatory effects on the vascular wall. Moreover, it modifies the vascular intracellular signaling and has indirect antioxidant effects on the human myocardium. On the other hand, there are studies suggesting that increased levels of adiponectin are paradoxically associated with a worse prognosis in heart failure syndrome, although the mechanisms are not clear. Conclusion: it is not clear whether adiponectin levels have any clinical significance for risk stratification in cardiovascular disease or if they simply reflect the activation of complex underlying mechanisms. Changes in lifestyle and some drug treatments for hypertension and coronary heart disease have shown significant effect to increase adiponectin levels, and simultaneously decrease in insulin resistance and endothelial dysfunction.

show abstract

Section: Biosynthesis Of Adiponectin and Receptorsmentioning

confidence: 99%

Section: Biosynthesis Of Adiponectin and Receptorsmentioning

confidence: 99%

Section: Obesity and Adiponectinmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between adiponectin, obesity and insulin resistance

Balsan¹,

Vieira²,

Oliveira³

et al. 2015

Rev. Assoc. Med. Bras.

144

100

View full text Add to dashboard Cite

show abstract

“…Adiponectin levels are lower in patients with essential hypertension and type-2 diabetes, and adiponectin is associated with insulin resistance, triglycerides and HDL cholesterol levels (Lihn, Pedersen, & Richelsen, 2005;Nigro et al, 2014;Vaiopoulos, Marinou, Christodoulides, & Koutsilieris, 2012). Given its role in metabolic diseases, adiponectin may be important in tracking and diagnosing some of the most rapidly growing and costly diseases in the United States (e.g., prediabetes/insulin resistance, metabolic syndrome, and vascular disease; Ebrahimi-Mamaeghani, Mohammadi, Arefhosseini, Fallah, & Bazi, 2015;Lopez-Jaramillo et al, 2014;Stojanović, Ilić, Ilić, Petrović, & Djukić, 2015).…”

Section: Introductionmentioning

confidence: 99%

Adiponectin: Serum-saliva associations and relations with oral and systemic markers of inflammation

Riis

Bryce

et al. 2017

Peptides

View full text Add to dashboard Cite

This study addresses gaps in our understanding about the validity and utility of using salivary adiponectin to index serum adiponectin levels. Matched blood and saliva samples were collected on a single occasion from healthy adults (n= 99; age 18-36 years, 53% male). Serum and saliva was assayed for adiponectin and inflammatory cytokines (IL-1β, IL-6, IL-8, TNFα), and saliva was also assayed for markers of blood contamination (transferrin), total protein (salivary flow rate) and matrix metalloproteinase-8 (MMP-8). We examined the extent to which salivary adiponectin was associated with serum adiponectin, and the influence of potential confounders on the serum-saliva correlation, including age, sex, body mass index, and markers of inflammation, oral health, salivary blood contamination, and flow rate. Findings revealed a modest serum-saliva association for adiponectin, and strong positive associations between salivary adiponectin and salivary levels of inflammatory cytokines, MMP-8, transferrin, and total protein. By contrast, salivary adiponectin was not related to serum levels of inflammatory activity. The magnitude of the serum-saliva association was strengthened when controlling for total protein in saliva, blood leakage into oral fluid, salivary inflammatory cytokines, and MMP-8. The pattern of findings extends our understanding of salivary adiponectin and its potential use as an index of circulating adiponectin levels.

show abstract

“…7) In clinical practice, pioglitazone has become a standard therapy for DM. By activating peroxisome proliferator-activated receptor-gamma (PPAR-gamma), pioglitazone acquires several pleiotropic properties such as inhibiting inflammatory and oxidant processes, [8][9][10][11][12] which may contribute to attenuating atrial fibrosis in the setting of AF. Therefore, it has attracted much attention as a new upstream therapy in recent studies on DM patients with AF.…”

mentioning

confidence: 99%

Beneficial Effects of Pioglitazone on Retardation of Persistent Atrial Fibrillation Progression in Diabetes Mellitus Patients

Liu

Wang

2014

Int. Heart J.

View full text Add to dashboard Cite

SummaryThis study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects.A total of 146 diabetes mellitus (DM) patients with firstly identified persistent AF were selected. Seventy patients were randomized into the pioglitazone (30 mg/day) group and 76 into the placebo group. Pro-collagen type I carboxyterminal peptide (PICP), advanced glycation end products (AGEs), and angiotensin II were assayed and left atrial diameter (LA diameter) was measured at the first presence of persistent AF, and at 6 and 14 months of follow-up. The time point of identification of permanent AF and the incidence of permanent AF in the patients were all recorded.Thirty-seven (49%) of the 76 patients in the placebo group and 21 (30%) of the 70 patients in the pioglitazone group progressed to permanent AF (P = 0.028). No significant differences existed in the follow-up time (20.5 ± 3.97 months for pioglitazone group versus 20.9 ± 4.14 months for placebo group) between the two groups (P = 0.535). In the pioglitazone group, no significant change was found in angiotensin II level. The PICP level did not change significantly at 6-months of follow-up, but decreased significantly at 14-months of follow-up (P = 0.032). The AGE (P = 0.037 at 6-month follow-up, P < 0.035 at 14-month follow-up) level was significantly lower at both 6 and 14-months of followup.By lowering the PICP level, pioglitazone treatment may decrease the incidence of permanent AF in DM patients with persistent AF, which may be associated with the suppressing effect of pioglitazone on AGEs. (Int Heart J 2014; 55: 499-505)

show abstract

The role of adiponectin in human vascular physiology

Cited by 87 publications

References 68 publications

Relationship between adiponectin, obesity and insulin resistance

Relationship between adiponectin, obesity and insulin resistance

Adiponectin: Serum-saliva associations and relations with oral and systemic markers of inflammation

Beneficial Effects of Pioglitazone on Retardation of Persistent Atrial Fibrillation Progression in Diabetes Mellitus Patients

Contact Info

Product

Resources

About